Sandra Flórez

• Leading medical strategy for multiple products including : immunology, neurosciences, diabetes and osteoporosis (biotechnology products), developing and implemented regional medical strategy for this therapeutic areas, being recognized and awarded by business as a strategic partner for the development of results and contributing to the financial results for Colombia affiliate
• KOL engagement, establishing and maintaining high value relationships with key opinion leaders, with high qualifications in medical education programs.
• Accelerate regulatory approvals for Galcanezumab, Tirzepatide
• Research expertise: Leading the team for achieving ALAFOS (RWE generation) publication plan for osteoporosis in Latin America
• Significant contributions to final analysis and coordinating authors Final publication across Asia, Pacific, Middle East and Latam and being main author The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS) - PubMed
• Leading LATAM publication Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS) | Advances in Rheumatology | Full Text
• Multiple encores presented in national congresses
• Scientific data dissemination/exchange in scientific exchange meeting, educational meeting, encore presentations at congresses, digital communications with HCPs, and promotional events, being evaluated as high-quality events
• Active participation in steering committee to better decision making for the affiliate
• Leading the implementation of first MSL in Lilly Colombia, including territory management to maximize MSL Scientific/Technical role and continued development of high-quality relations with experts, with the development of a new in industry physician in the role
• Regulatory support activities for the region: adapting scientific content for dossier submission, participation in meetings with regulatory authorities (alone or with key scientific expert) when queries arise.
• Patient support program oversight achieving no findings
• Risk mitigation activities for pharmacovigilance and promotion
• Successful medical affairs point of contact for all relevant stakeholders in all Lilly therapeutic areas when needed

Pain and Palliative Care Professor.

Impacted public health policies about opioid availability in Colombia

• Define priorities for Medical Affairs Area, design medical strategic plans and ensure scientific leadership is translated and implemented
• Develop a medical department with right capabilities: measure competencies for medical team and establish a training curriculum for Medical Manager
• Medical governance activities in compliance with Mundipharma procedures: medical information, pharmacovigilance, HCP payments and relationships
• Ensure the minimum findings in corporate and pharmacovigilance audits
• Development and executing medical plans for Difolta and Ophthalmology products
• Identification, building and leverage of relationships with national Key Opinion Leaders and scientific societies
• Sales force training
• Development of educational materials for HCP and patients
• Identification of Initiated Investigator Initiatives
• Establishment of a pharmacovigilance process and standard operating procedure

• Development and executing initiatives for launch readiness (Ibrutinib, Simponi and Stelara) and life cycle management of products (Remicade, Prograf, Durogesic, Zytiga, Ribomustin, Yondelis, Durogesic, Dacogen)
• Successful transition to a new vendor for patient support program. Successful transfer of Remicade program from MSD to Janssen according to compliance standards and local regulation. Implementation of all the quality assurance activities and quality audit related to Patient Support Programs
• Leading and feasibilities for a trial in prostate cancer
• Assure talent retention and development of people in charge (1 Medical Manager, 1 Junior Medical Manager, Patient Program Analyst and 4 Medical Scientific Liaison)
• Lead excellence, efficiency and process improvement in medical department (developments in patient support programs, samples, continuous medical education policies, interaction with patients, counterfeit & smuggling)
• Support regional activities for launch readiness of Esketamine
• Identification, building and leverage opportunities for Zytiga local studies
• Provide key information to access team to gain access to key formulary (Durogesic)

• Maintain Medical Strategies Focused on main customers (payers, hospitals, patients and government): Implementation of a Center of Excellence in Hemophilia project according to EFQM standards
• Implementation of a virtual conference cycle on pediatric transplant for Colombian Society of Pediatric Nephrology, for high quality skills
• Develop and maintain medical strategies focused on portfolio optimization and promotional alternatives: Take advantage of the exclusiveness approved indications for Genotropin by supporting the creation of guidelines to make limits of GH Rx
• Achieve commitment of transplant center and make Rapamune an strategic partner in kidney transplant: Implementation of a virtual conference cycle on pediatric transplant for Colombian Society of Pediatric Nephrology, for high quality skills on team work, and being recognized by District Manager and Field Force as a key actor on business plan implementation
• Lead scientific strategy for Hemophilia portfolio (BeneFIX, Xyntha), immunology (Rapamune) and Endocrinology (Genotropin) in institutional business unit.